Altogether, targeting BET proteins such as BRD4 by small molecule inhibitors of BET proteins is potent therapeutic strategy to efficiently inhibit the high-risk NB by downregulating MYCN expression (Liu et al., 2016) (Figure 1). Here, BRD4 is linked to neuroblastoma.